Bronchogen

Bronchogen is a synthetic tetrapeptide, Ala-Asp-Glu-Leu, studied primarily in respiratory and molecular models. The most defensible evidence includes rat obstructive lung pathology models and in vitro DNA thermostability work. In NO2-induced rat models resembling chronic obstructive pulmonary pathology, Bronchogen administration was reported to reduce bronchial epithelial remodeling, normalize bronchoalveolar inflammatory cell and cytokine profiles, increase secretory IgA, and restore surfactant protein B in a related study. A biophysical study reported that Bronchogen increased DNA melting temperature under experimental conditions. This supports a research page focused on bronchial epithelial remodeling, inflammatory-pathway models, local immunity markers, surfactant biology, and peptide-DNA interaction.

Obstructive Lung Pathology Models

In rat NO2-induced obstructive lung pathology models, Bronchogen was associated with reduced bronchial epithelial remodeling and improved inflammatory and surfactant markers ^[1][2].

DNA Thermostability Research

In vitro microcalorimetry work found Bronchogen increased the melting temperature of calf thymus and mouse liver DNA, supporting peptide-DNA interaction research ^[3].

Evidence Boundary

Rat COPD-like model findings do not establish treatment for COPD, asthma, bronchitis, infections, or lung repair in humans ^[1][2].

Animal and In Vitro Evidence

Bronchogen evidence is primarily animal and in vitro; no robust human safety trials or regulatory prescribing information were found ^[1][2][3].

Mechanistic Caution

Because Bronchogen may interact with DNA under experimental conditions, content should stay mechanistic and should not imply safety from short peptide size alone ^[3].